Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA

Abstract

Introduction and Objective: Persistence with the injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for weight management has been studied extensively, but drivers of persistence are not well characterized. We sought to identify predictors of persistence in a US real-world population. Methods: Adults (≥18 years old) who had a first claim for semaglutide for weight management (index date) between June 4, 2021 and July 1, 2023 were identified in the IQVIA Ambulatory Electronic Medical Records database, linked to PharMetrics® Plus. Individuals required ≥1 year of continuous enrollment pre-index and ≥1 year of follow-up data. Individuals with previous bariatric surgery were excluded. Discontinuation was indicated by >90 days not covered by the medication. Factors associated with persistence were identified using logistic regression. Results: In total, 42,028 individuals were included. Overall, 78.9% were women and 85.5% were aged ≥35 years; 39.5% had hypertension and 9.4% had T2D. At month 12, 38% were persistent on semaglutide. Predictors associated with persistence (p<0.05) were previous use of liraglutide for weight management (odds ratio [OR] 1.69), age ≥35 years (OR 1.63), and, among people with diabetes, use of other GLP-1RAs (OR 1.21). The following factors were negatively associated with persistence (p<0.05): male sex (OR 0.93), previous use of phentermine (OR 0.87), insulin use in people with diabetes (OR 0.79), and preexisting comorbidities (OR: musculoskeletal pain, 0.95; cerebrovascular disease, 0.84; ischemic heart disease, 0.84; T2D, 0.79; peripheral artery disease, 0.73). Conclusion: In a US real-world population, familiarity with the GLP-1RA class of medications appeared to help with persistence. An additional focus for obesity management with semaglutide should be to provide guidance on what to expect on the treatment journey, in particular for patients at higher risk of discontinuing treatment. Disclosure: W.H. Polonsky: Consultant; Abbott. Research Support; Abbott. Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. Other Relationship; Ascensia Diabetes Care. R. Arora: Employee; Novo Nordisk, IQVIA Inc. J. Fernandes: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. T. Arnaut: Employee; Novo Nordisk A/S, Roche Diabetes Care.

Overview

Integrity signals

Registry

Crossref · 10.2337/db25-786-p

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 1

Metadata

Authors
POLONSKY, W. H., ARORA, R., FERNANDES, J., & ARNAUT, T.
Affiliations
San Diego, CA, Bangalore, India, Søborg, Denmark
Venue
Diabetes
Published
2025-06-20
Volume
74
Issue
Supplement_1
ISSN
0012-1797 (ISSN-L)
OpenAlex
W4411291513
Cited by
1
References
0
Citations by year
2026: 1
FWCI
0.57
Type
journal article
Language
en
Open access
closed
Locations
Diabetes (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, weight management, treatment persistence, GLP-1 receptor agonists, obesity, predictors of discontinuation, liraglutide, phentermine, type 2 diabetes, comorbidities, sex differences, age, insulin use, real-world evidence, United States adults

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA. https://app.cochat.ai/papers/10.2337/db25-786-p
The paper
POLONSKY, W. H., ARORA, R., FERNANDES, J., & ARNAUT, T. (2025). 786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA. Diabetes. https://doi.org/10.2337/db25-786-p

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.